This content is from: Features
Repurposed drugs and your IP strategy
Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here